PARTI Overview Alnylam Pharmaceuticals, Inc. (also referred to as Alnylam, the Company, we, our or us) is a global commercial-stage biopharmaceutical company developing novel therapeutics based on ribonucleic acid interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. By harnessing the RNAi pathway, we have pioneered a new class of innovative medicines, known as RNAi therapeutics. RNAi therapeutics a...
Q2 FY2026 — expected 2026-09-20
| Type | Subject | Detail | Quarter |
|---|---|---|---|
| topic_mention | ALNY | discussed Artificial Intelligence | Q3 FY2025 |
| topic_mention | ALNY | discussed Blockchain & Crypto | Q3 FY2025 |
| topic_mention | ALNY | discussed Supply Chain | Q3 FY2025 |
| topic_mention | ALNY | discussed Regulation | Q3 FY2025 |
| topic_mention | ALNY | discussed Sovereign & Government | Q3 FY2025 |
| topic_mention | ALNY | discussed Automotive | Q3 FY2025 |
| topic_mention | ALNY | discussed Healthcare & Bio | Q3 FY2025 |
| guidance | ALNY | guided guidance are non - GAAP financial measures that exclud e from the corresponding GAAP measures stock - based compensation expense estimated at $345M - $375M in both the Prior FY 2025 Guidance and | Q3 FY2025 |
| guidance | ALNY | guided Guidance • Total TTR Net Product Revenues (PN & CM) (AMVUTTRA, ONPATTRO) $2,175 to $2,275 million | Q3 FY2025 |
| guidance | ALNY | guided Guidance Non - GAAP Combined R&D and SG&A Expenses 3 $2,100 to $2,200 million | Q3 FY2025 |
| guidance | ALNY | guided FY 2025 Guidance and the Updated FY 2025 Guidance Item Total Net Product Revenues 1 $2,650 to $2,800 million | Q3 FY2025 |
| topic_mention | ALNY | discussed Supply Chain | Q4 FY2024 |
| topic_mention | ALNY | discussed Regulation | Q4 FY2024 |
| topic_mention | ALNY | discussed Sovereign & Government | Q4 FY2024 |
| topic_mention | ALNY | discussed Automotive | Q4 FY2024 |
| topic_mention | ALNY | discussed Healthcare & Bio | Q4 FY2024 |
| topic_mention | ALNY | discussed Platform & Ecosystem | Q4 FY2024 |
| guidance | ALNY | guided Guidance 12 Disrupting an Expanding Growth Market 1 Information based on Alnylam modeling data Significant Unmet Patient Need ~80% ATTR - CM patients undiagnosed globally 1 RAPID KNOCKDOWN | Q4 FY2024 |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-12 | 2025-12-31 | 0001628280-26-007497 | EDGAR | 108K words |
| 2025-02-13 | 2024-12-31 | 0001178670-25-000026 | EDGAR | — |
| 2024-02-15 | 2023-12-31 | 0001178670-24-000008 | EDGAR | — |
| 2023-02-23 | 2022-12-31 | 0001178670-23-000005 | EDGAR | — |
| 2022-02-10 | 2021-12-31 | 0001178670-22-000013 | EDGAR | — |
| 2021-02-11 | 2020-12-31 | 0001178670-21-000010 | EDGAR | — |
| 2020-02-13 | 2019-12-31 | 0001178670-20-000004 | EDGAR | — |
| 2019-02-14 | 2018-12-31 | 0001564590-19-003022 | EDGAR | — |
| 2018-02-15 | 2017-12-31 | 0001564590-18-002152 | EDGAR | — |
| 2017-02-15 | 2016-12-31 | 0001564590-17-001649 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-07-30 | 2026-06-30 | 0001178670-26-000062 | EDGAR | — |
| 2026-04-30 | 2026-03-31 | 0001628280-26-028605 | EDGAR | — |
| 2025-10-30 | 2025-09-30 | 0001628280-25-047345 | EDGAR | 62K words |
| 2025-07-31 | 2025-06-30 | 0001178670-25-000090 | EDGAR | — |
| 2025-05-01 | 2025-03-31 | 0001178670-25-000052 | EDGAR | — |
| 2024-10-31 | 2024-09-30 | 0001178670-24-000053 | EDGAR | — |
| 2024-08-01 | 2024-06-30 | 0001178670-24-000041 | EDGAR | — |
| 2024-05-02 | 2024-03-31 | 0001178670-24-000023 | EDGAR | — |
| 2023-11-02 | 2023-09-30 | 0001178670-23-000023 | EDGAR | — |
| 2023-08-03 | 2023-06-30 | 0001178670-23-000015 | EDGAR | — |
| 2023-05-04 | 2023-03-31 | 0001178670-23-000011 | EDGAR | — |
| 2022-10-27 | 2022-09-30 | 0001178670-22-000026 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-07-30 | 0001178670-26-000060 | EDGAR | — |
| 2026-05-27 | 0001628280-26-038499 | EDGAR | — |
| 2026-04-30 | 0001628280-26-028601 | EDGAR | — |
| 2026-03-04 | 0001628280-26-014728 | EDGAR | 1K words |
| 2026-02-12 | 0001628280-26-007491 | EDGAR | — |
| 2026-01-12 | 0001628280-26-001755 | EDGAR | — |
| 2025-12-11 | 0001193125-25-315047 | EDGAR | — |
| 2025-12-03 | 0001628280-25-055084 | EDGAR | — |
| 2025-10-30 | 0001628280-25-047342 | EDGAR | — |
| 2025-10-03 | 0001193125-25-230201 | EDGAR | — |
213 total filings indexed. 181 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| Call Date | Quarter | Title |
|---|---|---|
| — | Q3 FY2025 | ALNY Q3 FY2025 Earnings Call Transcript |
| — | Q4 FY2024 | ALNY Q4 FY2024 Earnings Call Transcript |
Access full transcripts via API (JSON) — includes speakers, key metrics, competitive mentions, and origin provenance chain.
| CIK | 0001178670 |
| Ticker | ALNY |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Website | https://www.alnylam.com |
| Listed | 2004-05-28 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/ALNY (~200 tokens, structured JSON with cryptographic provenance)